Neos Therapeutics (NEOS) Stock Price & Overview
NASDAQ:NEOS
Current stock price
The current stock price of NEOS is 1.15 null. Today NEOS is down by -2.54%. In the past month the price increased by 13.86%. In the past year, price increased by 64.29%.
NEOS Key Statistics
- Market Cap
- 57.221M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.44
- Dividend Yield
- N/A
NEOS Stock Performance
NEOS Stock Chart
NEOS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NEOS. When comparing the yearly performance of all stocks, NEOS is one of the better performing stocks in the market, outperforming 76.83% of all stocks.
NEOS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NEOS. NEOS has a bad profitability rating. Also its financial health evaluation is rather negative.
NEOS Earnings
NEOS Forecast & Estimates
NEOS Financial Highlights
Over the last trailing twelve months NEOS reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -38.35% | ||
| ROA | -33.84% | ||
| ROE | N/A | ||
| Debt/Equity | -0.67 |
NEOS Ownership
About NEOS
Company Profile
Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.
Company Info
Neos Therapeutics
2940 NORTH HIGHWAY 360
GRAND PRAIRIE TX 75050
CEO: Gerald McLaughlin
Phone: 972-408-1300
Neos Therapeutics / NEOS FAQ
Can you describe the business of Neos Therapeutics?
Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.
Can you provide the latest stock price for Neos Therapeutics?
The current stock price of NEOS is 1.15 null. The price decreased by -2.54% in the last trading session.
Does Neos Therapeutics pay dividends?
NEOS does not pay a dividend.
How is the ChartMill rating for Neos Therapeutics?
NEOS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for NEOS stock?
Neos Therapeutics (NEOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.44).